ArticleScientific reports2018
Probiotics in human gut microbiota can degrade host glycosaminoglycans.
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed.
- Non-Enzymatic Browning of Collagen Hydrolysates with Chondroitin Sulfate Disaccharides from Turkey and Shark Cartilage.Molecules (Basel, Switzerland) · 2026Article
- Comparative Genomic and Functional Profiling of ECM-Targeting Enzymes inbioRxiv : the preprint server for biology · 2026Article
- Insights into the proteome of next-generation probiotic Faecalibacterium duncaniae A2-165 through label-free proteomics approach.BMC microbiology · 2026Article
- Revisiting Hyaluronan Catabolism in Bacteroides: Pathway Conservation, Overlooked Proteins, and Predictive Accuracy.MicrobiologyOpen · 2026Article
- Molecular evolution and diversity of isomerase-reductase clusters involved in the bacterial metabolism of glycosaminoglycans.mSphere · 2026Article
- Antibacterial Immunotherapy: Mechanistic Insights, Emerging Therapeutic Strategies, and Clinical Translation.Infection and drug resistance · 2026Review
- Assessment of pathogenic potential in non-pathogenic industrially relevant bacteria.Access microbiology · 2026Article
- The NagY antiterminator inMicrobiology spectrum · 2025Article
- Metabolic pathways associated with Firmicutes prevalence in the gut of multiple livestock animals and humans.Animal microbiome · 2025Article
- Biochemical Characterization of Hyaluronate Lyase CpHly8 from an Intestinal Microorganism Clostridium perfringens G1121.Applied biochemistry and biotechnology · 2025Article
- Unveiling the role of the upper respiratory tract microbiome in susceptibility and severity to COVID-19.Frontiers in cellular and infection microbiology · 2025Article
- Olanzapine affects bone formation via oralFrontiers in cellular and infection microbiology · 2025Article
- Microbiota and inflammatory bowel disease: the dual effect mechanism of polysaccharide therapy.Frontiers in immunology · 2025Review
- A comprehensive review on microbial hyaluronan-degrading enzymes: from virulence factors to biotechnological tools.Bioresources and bioprocessing · 2024Review
- Identification and Characterization of a Highly Active Hyaluronan Lyase fromMarine drugs · 2024Article
- Coaggregated E. faecalis with F. nucleatum regulated environmental stress responses and inflammatory effects.Applied microbiology and biotechnology · 2024Article
- Host-microbiome orchestration of the sulfated metabolome.Nature chemical biology · 2024Review
- The Role of Metabolomics and Microbiology in Urinary Tract Infection.International journal of molecular sciences · 2024Review
- Characterising glycosaminoglycans in human breastmilk and their potential role in infant health.Microbial cell (Graz, Austria) · 2024Article
- The Effect ofDermatopathology (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glycosaminoglycans (GAGs) (e.g. heparin, chondroitin sulfate, and hyaluronan) show various significant physiological functions as a major component of extracellular matrix in animals. Some bacteria target GAGs for adhesion and/or infection to host cells, although no probiotics have been known to degrade GAGs. Here, we show GAG degradation by probiotics from human gut microbiota and their adhesion to human intestinal cells through a GAG. GAG-degrading bacteria were isolated from human faeces and identified as Enterococcus faecium, and some typical probiotics such as Lactobacillus casei, Lactobacillus rhamnosus and Enterococcus faecalis were also found to degrade heparin. GAG-degrading lactobacilli and enterococci including the isolated E. faecium possessed a genetic cluster encoding GAG-degrading/metabolising enzymes in the bacterial genome. KduI and KduD enzymes encoded in the GAG cluster of L. rhamnosus functioned as 4-deoxy-l-threo-5-hexosulose-uronate ketol-isomerase and 2-keto-3-deoxy-d-gluconate dehydrogenase, respectively, both of which were crucial for GAG metabolism. GAG-degrading L. rhamnosus and E. faecium attached to human intestinal Caco-2 cells via heparin. Some species of Bacteroides, considered to be the next generation probiotics, degraded chondroitin sulfate C and hyaluronan, and genes coding for the Bacteroides GAG-degrading enzyme were frequently detected from human gut microbiota. This is the first report on GAG-degrading probiotics in human gut microbiota.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.